Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Cytokine Release Syndrome × otelixizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Epstein-Barr Virus Infections 1 Diabetes Mellitus, Type 1 1 Diabetes Mellitus 1 Cytokine Release Syndrome 1

Interventions

otelixizumab 1 fludarabine phosphate 1 fludarabine 1 Metoprolol 1 Interleukin 1 Receptor Antagonist Protein 1 Infliximab 1 Etanercept 1 Cyclophosphamide 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02000817 2019-06-24

Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients

GlaxoSmithKline

Phase 1/2 Completed

30 enrolled 21 charts

Cytokine Release Syndrome, Diabetes Mellitus, Diabetes Mellitus, Type 1, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡